Hanshow Technology
301275
Yong Jie New Material
603271
ZZT
873726
BEOKA
870199
Geovis Insighter Technology
920116
CN Stock MarketDetailed Quotes
688016 Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd.
- 92.59
- -0.39-0.42%
Market Closed Mar 11 15:00 CST
11.41BMarket Cap17.36P/E (TTM)
92.89High91.71Low14.31KlotVolume92.41Open92.98Pre Close132.04MTurnover1.16%Turnover Ratio23.18P/E (Static)123.26MShares133.9352wk High2.94P/B11.41BFloat Cap76.9752wk Low111.58Limit Up123.26MShs Float315.53Historical High74.38Limit Down1.27%Amplitude60.13Historical Low3.68Dividend TTM92.30Avg Price7.91KlotAsk3.97%Div YieldTTM100Lot Size5.86KlotBid
Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd. News
Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd. (688016.SH): The transjugular intrahepatic puncture kit has obtained the medical instruments registration certificate.
On March 7, Gelonghui reported that Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd. has obtained a medical instruments registration certificate issued by the Shanghai Municipal Medical Products Administration for the product named: Transjugular Intrahepatic Portosystemic Shunt Kit. This product is the company's first tumor interventional product approved for market, enriching the existing variety of the company's products. In addition to this product, Shanghai MicroPort has multiple tumor interventional products under research, including the HepaFlow TIPS covered bracket system, as well as an embolization hemostasis system, microspheres, microcatheters, and more. As more high-quality innovations with universal potential emerge.
Cardiac Healthcare: Cardiac Healthcare: 2024 Annual Results Express Announcement
Cardiac Healthcare: 2024 Annual Results Express Announcement
Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd. (688016.SH): In 2024, the net income is 0.498 billion yuan, an increase of 1.1% year-on-year.
On February 27, Gelonghui reported that Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd. (688016.SH) announced the annual performance report for 2024. During the reporting period, the company achieved total operating revenue of 1,206.4732 million yuan, an increase of 1.60% year-on-year; operating profit of 658.3393 million yuan, an increase of 14.70% year-on-year; total profit of 648.7459 million yuan, an increase of 13.40% year-on-year; net income attributable to the parent company's owners of 497.8582 million yuan, an increase of 1.10% year-on-year; net income attributable to the parent company's owners after deducting non-recurring gains and losses of 391.421 million yuan.
Is Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Stock's Recent Performance A Reflection Of Its Financial Health?
Sinolink: The rising enthusiasm for HEALTH CARE A applications is worth investing in; the traditional main line may welcome a reversal in the quarterly reports.
With the development and progress of AI technology, AI continuously makes new advancements in empowering medical and healthcare, promoting industry upgrades, and its application in the medical and health field is expected to enter an accelerated development stage.
Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd. (688016.SH): has repurchased a total of 0.727 million shares.
On February 6, Gelonghui reported that Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd. (688016.SH) announced that as of January 31, 2025, the company has accumulated repurchased 726,989 shares through the centralized bidding trading system of the Shanghai Stock Exchange (Phase II), with a highest transaction price of 119.82 yuan/share, a lowest transaction price of 104.95 yuan/share, and the total funds paid amounting to 78,373,496.42 yuan (excluding stamp duty, transaction commission, and other trading expenses).
Hong Kong stock market movement | MICROPORT (00853) surged nearly 4% as its subsidiary Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd. is expected to see a year-on-year increase in net profit attributable to the parent company from 0.01% to 9.86% i
MICROPORT (00853) rose nearly 4%, as of the time of writing, it increased by 3.83%, priced at 5.97 Hong Kong dollars, with a transaction amount of 22.5752 million Hong Kong dollars.
Returns On Capital At Shanghai MicroPort Endovascular MedTech (SHSE:688016) Have Hit The Brakes
MicroPort Scientific's Subsidiary Expects to Book Up to 9.86% Higher Attributable Net Profit for 2024
MICROPORT: Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd. expects a net income of 0.4925 billion to 0.541 billion yuan for 2024, an increase of 0.01% to 9.86% year-on-year.
MICROPORT (00853) announced that Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd. (688016.SH) is expected to achieve revenue of 1.1875 billion to 1.306 billion yuan in 2024, an increase of 0.02% to 10.01% year-on-year. It is expected that the net income attributable to the parent company's owners will be 0.4925 billion to -0.541 billion yuan in 2024, an increase of 0.01% to 9.86% year-on-year.
Heart Care: Heart Care: 2024 Annual Results Forecast
Cardiac Healthcare: 2024 Annual Results Forecast
Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd. (688016.SH): The net profit is expected to increase by 0.01% to 9.86% in 2024.
On January 20, Gelonghui reported that Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd. (688016.SH) announced its forecast for annual performance in 2024. According to preliminary calculations by the company’s finance department, it is expected to achieve revenue of 1.188 billion yuan to 1.306 billion yuan in 2024, an increase of 0.02% to 10.01% year-on-year. It is projected that the net income attributable to the owners of the parent company for the year 2024 will be 0.493 billion yuan to 0.541 billion yuan, an increase of 0.01% to 9.86% year-on-year. During the reporting period, the company’s innovative products include the Castor branched aortic covered brackets and delivery system, and the Minos abdominal aortic covered brackets.
Sinolink: The policy inflection point is clear, suggesting to start increasing allocation in the pharmaceutical sector.
In the segmented Industry, it is recommended to focus on allocating resources to Innovative Drugs and left-side Sectors (such as Medical Device, Traditional Chinese Medicine, Consumer Medical, chain pharmacies, etc.) for opportunities in reverse situations of individual stocks as the two main lines.
Sinolink: The market's attention to the left reversal of the pharmaceutical sector is increasing, with a focus on the related Sector of respiratory infections.
The proportion of influenza and other respiratory infections continues to rise, and it is recommended to closely monitor the infectious disease situation.
Sinolink: Major policies have been released, innovation remains the most important direction. The pharmaceutical and healthcare Industry has entered a performance window, focusing on reversal expectations.
The market has entered the window period for annual and quarterly reports, and it is recommended to actively pay attention to the fundamental Bearish clearance of left-side symbols (such as some Medical Devices, Traditional Chinese Medicine, pharmacies, chain Medical, CXO, etc.) and the implementation of centralized procurement policies.
Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Earnings Are Not Doing Enough For Some Investors
Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd. (688016.SH): The second phase has accumulated a buyback of 0.179 million shares of the company.
Gelonghui, January 2nd丨Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd. (688016.SH) announced that as of December 31, 2024, the company has cumulatively repurchased 178,968 shares through the centralized bidding trading system of the Shanghai Exchange (Phase II), with the highest repurchase price at 119.82 yuan/share and the lowest price at 109.26 yuan/share.
Shanghai MicroPort Endovascular MedTech Obtains Medical Device Registration for Catheter
